Report
Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.
North America Insulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type [Long Acting Insulin, Rapid Acting Insulins, Short-Acting Insulins and Traditional Human Insulins, Concentrated Insulins and Combination Insulins, Biosimilar Insulins, Glucagon-Like Peptide-1 (GLP-1), Pens and Needles, and Others]
- Report Code : BMIRE00027247
- Pages : 174
The insulin market in North America is expected to grow from US$ 23,946.85 million in 2022 to US$ 43,517.93 million by 2028. It is estimated to grow at a CAGR of 10.5% from 2022 to 2028.
Rapid Technological Developments in Insulin Delivery Devices by Major Players Boosts
As the prevalence of diabetes is increasing across North America, the demand for more advanced therapeutic products is on the rise. Companies in the insulin market actively support public and private research and academic institutes for encouraging research activities. A few of the recent developments related to rapid technological advancements in the insulin market are mentioned below:
• In October 2021, Tonghua Dongbao Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration (NMPA) for the clinical trial of its ultra-rapid-acting insulin injection, BC Lispro. Currently, the drug is in phase III clinical trial initiated in China.
• In May 2021, Bigfoot Biomedical received 510(k) clearance from the USFDA for its Bigfoot Unity Diabetes Management System offered with connected smart pen caps that recommend insulin doses for people using the multiple daily injections (MDI) therapy.
Such technological advancements in insulin delivery devices are boosting the growth of the North America insulin market.
Market Overview
The North America insulin market has been segmented into the US, Canada, and Mexico, wherein the US accounts for a maximum share. The market growth in the region is attributed to the rising prevalence of diabetes and obesity, coupled with the increasing awareness about diabetes care. According to the National Diabetes Statistics Report 2020, ~30.3 million people in the US have diabetes, representing 94% of the total population. Among the diabetic population, ~5% are diagnosed with type 1 diabetes while 90–95% have type 2 diabetes. From more than 30 million Americans with diabetes, ~7.4 million rely on insulin to manage their condition. In addition, data also revealed ~86 million adults aged 18 or above and ~23.1 million elders of age 65 were prediabetic. Diabetes is also a leading cause of blindness and end-stage renal diseases or renal failure among adults.
North America Insulin Market Revenue and Forecast to 2028 (US$ Million)
North America Insulin Market Segmentation
The North America insulin market is segmented into type and country. Based on type, the market is segmented into long acting insulin, rapid acting insulin, short acting insulin and traditional human insulin, concentrated insulin and combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen and needle, and others. The long acting insulin segment accounted for the largest market share in 2022 .
The North America insulin market for the long acting insulin segment is subsegmented into Levemir, lantus, basaglar, and tresiba. The tresiba segment held the largest market share in 2022 .
The North America insulin market for the short acting insulin and traditional human insulin segment is subsegmented into Novolin R, Humalin R, Insuman, and others. The insuman segment held the largest market share in 2022.
The North America insulin market for the concentrated insulin and combination insulin segment is further segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held the largest market share in 2022 .
The North America insulin market for the biosimilar insulin segment is further segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment accounted for a larger market share in 2022 .
Based on country, the insulin market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.
Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt are the leading companies operating in the insulin market in the region.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Insulin Market – By Type
1.3.2 North America Insulin Market – By Country
2. North America Insulin Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Insulin Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.2.1 Expert Opinion
5. North America Insulin Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Incidence of Diabetes
5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Major Players
5.2 Market Restraints
5.2.1 Risks Associated with Insulin Delivery Devices
5.3 Market Opportunities
5.3.1 Insufficient Competition from Biosimilars
5.4 Future Trends
5.4.1 Regeneration of Diabetic Pancreas with Advanced Transplants
5.5 Impact Analysis
6. Insulin Market– North America Analysis
6.1 North America Insulin Market Revenue Forecast and Analysis
7. North America Insulin Market Analysis – By Type
7.1 Overview
7.2 North America Insulin Market Revenue Share, by Type (2021 and 2028)
7.3 Long Acting Insulin
7.3.1 Overview
7.3.2 Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Levemir
7.3.2.1.1 Overview
7.3.2.1.2 Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Lantus
7.3.2.2.1 Overview
7.3.2.2.2 Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.3 Basaglar
7.3.2.3.1 Overview
7.3.2.3.2 Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.4 Tresiba
7.3.2.4.1 Overview
7.3.2.4.2 Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Rapid Acting Insulins
7.4.1 Overview
7.4.2 Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Novolog
7.4.2.1.1 Overview
7.4.2.1.2 Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Humalog
7.4.2.2.1 Overview
7.4.2.2.2 Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.3 Admelog
7.4.2.3.1 Overview
7.4.2.3.2 Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.4 Others
7.4.2.4.1 Overview
7.4.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Short Acting Insulins and Traditional Human Insulins
7.5.1 Overview
7.5.2 Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Novolin R
7.5.2.1.1 Overview
7.5.2.1.2 Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Humulin R
7.5.2.2.1 Overview
7.5.2.2.2 Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Insuman
7.5.2.3.1 Overview
7.5.2.3.2 Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.4 Others
7.5.2.4.1 Overview
7.5.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Concentrated Insulins and Combination Insulins
7.6.1 Overview
7.6.2 Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 NovoMix
7.6.2.1.1 Overview
7.6.2.1.2 NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.2 Ryzodeg
7.6.2.2.1 Overview
7.6.2.2.2 Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.3 Xultophy
7.6.2.3.1 Overview
7.6.2.3.2 Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.4 Soliqua/Suliqua
7.6.2.4.1 Overview
7.6.2.4.2 Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Biosimilar Insulins
7.7.1 Overview
7.7.2 Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.1 Insulin Glargine
7.7.2.1.1 Overview
7.7.2.1.2 Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.2 Human Insulin
7.7.2.2.1 Overview
7.7.2.2.2 Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.8 Glucagon-like peptide-1 (GLP-1)
7.8.1 Overview
7.8.2 Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.9 Pens and Needles
7.9.1 Overview
7.9.2 Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8. North America Insulin Market – Country Analysis
8.1 Overview
8.1.1 North America: Insulin Market, by Country, 2021 & 2028 (%)
8.1.1.1 US: Global Insulin market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.1.1 US: Insulin market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.1.2 US: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.1.2.1 US: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.1.2.2 US: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.1.2.3 US: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.1.2.4 US: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.1.2.5 US: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.2 Canada: Insulin market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.2.1 Canada: Insulin market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.2.2 Canada: Insulin Market , By Type, 2019–2028 (US$ Million)
8.1.1.2.2.1 Canada: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.2.2.2 Canada: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.2.2.3 Canada: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.2.2.4 Canada: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.2.2.5 Canada: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.3 Mexico: Insulin market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.3.1 Mexico: Insulin market – Revenue and Forecast to 2028 (US$ Million)
8.1.1.3.2 Mexico: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.3.2.1 Mexico: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.3.2.2 Mexico: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.3.2.3 Mexico: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.3.2.4 Mexico: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.3.2.5 Mexico: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
9. North America Insulin Market–Industry Landscape
9.1 Overview
9.2 Organic Developments
9.2.1 Overview
9.3 Inorganic Developments
9.3.1 Overview
10. Company Profile
10.1 Eli Lilly and Company
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 Novo Nordisk A/S
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Biocon
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Wockhardt
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 GlaxoSmithKline plc.
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 Sanofi
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Pfizer Inc.
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Merck & Co., Inc.
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Tonghua Dongbao Pharmaceutical Co., Ltd.
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
11. Appendix
11.1 About The Insight Partners
11.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Insulin Market, Revenue and Forecast, 2019–2028 (US$ Million)
Table 2. US: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. US: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 4. US: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 5. US: Insulin Market, By Short-acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 6. US: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 7. US: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 8. Canada: Insulin Market , By Type – Revenue and Forecast to 2028 (US$ Million)
Table 9. Canada: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 10. Canada: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada: Insulin Market, By Short acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 12. Canada: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 14. Mexico: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 15. Mexico: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 16. Mexico: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 17. Mexico: Insulin Market, By Short acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 18. Mexico: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 19. Mexico: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 20. Organic Developments in the Insulin Market
Table 21. Inorganic Developments in the Insulin Market
Table 22. Glossary of Terms, North America Insulin Market
LIST OF FIGURES
Figure 1. North America Insulin Market Segmentation
Figure 2. North America Insulin Market Segmentation, By Country
Figure 3. North America Insulin Market Overview
Figure 4. The Long Acting Insulin Segment Held Largest Share of Type in the Insulin Market
Figure 5. US Is Expected to Show Remarkable Growth During the Forecast Period
Figure 7. North America PEST Analysis
Figure 8. Expert Opinion
Figure 9. North America Insulin Market Impact Analysis of Drivers and Restraints
Figure 10. North America Insulin Market– Revenue Forecast and Analysis
Figure 11. North America Insulin Market Revenue Share, by Type (2021 and 2028)
Figure 12. North America Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. North America Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. North America Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. North America Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. North America Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. North America Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. North America Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. North America Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. North America Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. North America Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. North America Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. North America Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. North America Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. North America Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. North America Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. North America Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. North America NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. North America Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. North America Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. North America Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. North America Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. North America Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. North America Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. North America Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. North America Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. North America Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. North America Insulin Market, by Key Country – Revenue (2021) (US$ Million)
Figure 39. North America: Insulin Market, by Country, 2021 & 2028 (%)
Figure 40. US: Insulin market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Canada: Insulin market – Revenue and Forecast to 2028 (US$ Million)
Figure 42. Mexico: Insulin market – Revenue and Forecast to 2028 (US$ Million)
● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America insulin market.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the North America insulin market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth North America market trends and outlook coupled with the factors driving the insulin market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
The List of Companies – North America Insulin Market
● Biocon
● Eli Lilly and Company
● GlaxoSmithKline plc.
● Merck & Co., Inc.
● Novo Nordisk A/S
● Pfizer Inc.
● Sanofi
● Tonghua Dongbao Pharmaceutical Co., Ltd.
● Wockhardt
At 10.5% CAGR, the North America Insulin Market is speculated to be worth US$ 43,517.93 million by 2028, says The Insight Partners
According to The Insight Partners’ research, the North America insulin market was valued at US$ 23,946.85 million in 2022 and is expected to reach US$ 43,517.93 million by 2028, registering an annual growth rate of 10.5% from 2022 to 2028. Increase in incidence of diabetes and rapid technological developments in insulin delivery devices by major players are the critical factors attributed to the market expansion.
Diabetes is a life-threatening chronic disease with no specialized cure. It is mainly caused by the body’s incapacity to produce or effectively utilize the hormone insulin. This incapacity prevents the body from adequately regulating blood glucose levels. Incidence and prevalence of diabetes are rapidly increasing across the region. Type 2 diabetes is the most prevalent form of diabetes and has grown alongside cultural and societal changes. In high-income countries, up to 91% of adults with the disease have type 2 diabetes. According to the International Diabetes Federation (IDF), approximately 537 million people were living with diabetes in 2021, and it is expected to reach 643 million by 2030 and 783 million by 2045 across the region. Diabetes can lead to complications in many body parts and increase the risk of premature death. Primary complications include heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage. Patients who have diabetes require frequent monitoring and external administration of insulin. Thus, the rising prevalence of diabetes is driving the insulin market.
On the contrary, risks associated with insulin delivery devices hurdles the growth of North America insulin market.
Based on type, the North America insulin market is segmented into long acting insulin, rapid acting insulin, short acting insulin & traditional human insulin, concentrated insulin & combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen & needle, and others. The long acting insulin segment held 25.0% market share in 2022, amassing US$ 5,993.57 million. It is projected to garner US$ 10,734.80 million by 2028 to expand at 10.2% CAGR during 2022–2028.
Based on long acting insulin, the North America insulin market is sub-segmented into Levemir, lantus, basaglar, and tresiba. The tresiba segment held 47.6% market share in 2022, amassing US$ 2,855.54 million. It is projected to garner US$ 5,230.71 million by 2028 to expand at 10.6% CAGR during 2022–2028.
Based on rapid acting insulins the North America insulin market is sub-segmented into novolog, humalog, admelog, and others. The humalog segment held 45.5% market share in 2022, amassing US$ 1,665.34 million. It is projected to garner US$ 2,921.65 million by 2028 to expand at 9.8% CAGR during 2022–2028.
Based on short acting insulin and traditional human insulin, the North America insulin market is sub-segmented into Novolin R, Humalin R, Insuman, others. The insuman segment held 40.8% market share in 2022, amassing US$ 2,013.02 million. It is projected to garner US$ 3,634.27 million by 2028 to expand at 4.3% CAGR during 2022–2028.
Based on concentrated insulin and combination insulin, the North America insulin market is sub-segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held 40.5% market share in 2022, amassing US$ 394.32 million. It is projected to garner US$ 749.12 million by 2028 to expand at 11.3% CAGR during 2022–2028.
Based on biosimilar insulin, the North America insulin market is sub-segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment held 55.7% market share in 2022, amassing US$ 513.65 million. It is projected to garner US$ 1,486.37 million by 2028 to expand at 19.4% CAGR during 2022–2028.
Based on country, the North America insulin market is segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 84.8% market share in 2022. It was assessed at US$ 20,299.75 million in 2022 and is likely to hit US$ 36,602.93 million by 2028, exhibiting a CAGR of 10.3% during the forecast period.
Key players dominating the North America insulin market are Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt among others.
In 2021, Viatris launched a non-interchangeable Semglee in 2020 at a WAC price of $99, marking a steep discount off Lantus’ WAC of $284. In 2020, Pfizer showcased Phase I data from a study assessing PF-06882961, an oral small molecule glucagon-like peptide – 1 receptor (GLP-1 R) agonist in type 2 diabetes patients that showed significant promise in the reduction of glucose levels and body weight.
Related Reports
- $3,000.00 – $5,000.00
